Rizafilm

(rizatriptan)

Phase 3Small molecule

OOrganon and Co

Rizafilm is one of 38 small molecule programs targeting Headache. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Motion SicknessActive, not recruiting

MigraineActive, not recruiting

Motion SicknessPreclinical

Active, not recruiting

MigrainePhase 3

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Rizafilm

OOrganon and Co

Phase 3

8 2

Aimovig

Amgen

Preclinical

33 3

Emgality

Eli Lilly

Preclinical

19 4

Vyepti

Lundbeck

Preclinical

12 5

Bayer Aspirin

Bayer

Preclinical

2 6

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 7

Botox

RRevance Therapeutics, Inc.

Preclinical

9 8

Cervidil

Pfizer

Preclinical

1 9

Adempas

Bayer

Preclinical

1 10

Viagra

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Migraine8 trials

Two Rizatriptan Prescribing Portions for Treatment of Migraine

Completed·CClinvest·Phase 4·NCT00397254·197 enrolled

Rizatriptan 10 MG RPD in the Treatment of Acute Migraine

Completed·UUniversität Duisburg-Essen·Phase 4·NCT01057160·195 enrolled

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)

Completed·OOrganon and Co·Phase 3·NCT01001234·1,382 enrolled

Show 5 more trials

A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00246337·420 enrolled

Maximizing Outcomes in Treating Acute Migraine

Completed·AAxsome Therapeutics, Inc.·Phase 3·NCT03896009·1,594 enrolled

Rizatriptan for Episodic Dizziness in Vestibular Migraine

Completed·—·Phase 2/3·NCT02447991·223 enrolled

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)

Completed·OOrganon and Co·Phase 3·NCT00894556·109 enrolled

Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00443209·1,068 enrolled

Motion Sickness1 trial

Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?

Completed·UUniversity of Pittsburgh·N/A·NCT00360282·36 enrolled

Headache1 trial

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops

Withdrawn·HHenry M. Jackson Foundation for the Advancement of Military Medicine·N/A·NCT01306266

Oral1 trial

Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)

Completed·OOrganon and Co·Phase 3·NCT01286207·1,959 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 29, 1998

MAXALT-MLT

NDA NDA020865

Jun 29, 1998

MAXALT

NDA NDA020864

Feb 26, 2026

RIZAFILM

NDA NDA205394

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for rizatriptan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rizatriptan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rizatriptan. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA205394). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Rizafilm. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Organon and Co company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOrganon and Co

Patent Landscape[5]

Patent Cliff

Jul 30, 2034

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9301948Jul 30, 2034

Rizafilm

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Migraine8 trials

Motion Sickness1 trial

Headache1 trial

Oral1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News